Monday, September 14, 2026

When Does a Heart Blockage Need a Stent?

 When Does a Heart Blockage Need a Stent?


Introduction


                                            Image from The Keyhole clinic (2021)

Coronary artery disease (CAD) occurs when plaque builds up inside the coronary arteries, reducing blood flow to the heart and causing ischemia. CAD can cause chest pain, shortness of breath, heart attacks, and other serious complications. One treatment for these blockages blockages is percutaneous coronary intervention (PCI), a procedure that opens a closed off artery, often using a stent. However, not every blockage requires a stent. Researchers have been studying whether measuring how much a blockage actually limits blood flow can help doctors make better treatment decisions. A recent long term study examined whether using fractional flow reserve (FFR) to guide PCI improves outcomes for patients with coronary artery disease.

How Was This Study Done?

The researchers analyzed long term results from the FAME 2 clinical trial. Participants had stable CAD and coronary artery blockages that were evaluated using FFR. FFR is a measurement that determines whether a blockage significantly restricts blood flow to the heart. Patients with an FFR of 0.80 or lower were randomly assigned to receive either FFR guided PCI plus medical therapy or medical therapy alone. The researchers then followed these patients for more than 10 years and compared outcomes between the two groups. They specifically looked at major cardiovascular events, including death, heart attack, and the need for a second procedure on the same artery if a reblockage had occurred (Collet et al., 2026).

What Did They Find?

The researchers found that patients who received FFR-guided PCI had better overall outcomes than patients who received medical therapy alone. After a median follow up of approximately 11.2 years, the primary combined outcome occurred in 33.6% of patients who received PCI compared with 41.3% of those who received medical therapy alone (Collet et al., 2026). However, the difference was largely related to fewer urgent procedures in the PCI group. The researchers did not find a statistically significant reduction in death from any cause.

These results are interesting because they show that opening a blockage can reduce the likelihood of needing an urgent procedure later, but it does not necessarily mean that patients will live longer. I find the study convincing because the researchers used a randomized trial design and followed participants for more than a decade. However, the results should not be interpreted as meaning that every patient with CAD should receive a stent.

Putting It All in Context

This study demonstrates the importance of looking beyond the appearance of a blockage when treating CAD. A coronary artery may appear significantly narrowed on an imaging test, but that does not always mean that the blockage is restricting blood flow enough to require an intervention. FFR provides doctors with additional information about the blockage's actual effect on circulation.

The findings also support previous research showing that FFR-guided PCI can reduce urgent revascularization and improve symptoms in patients with stable CAD (De Bruyne et al., 2012). Fearon et al also revealed that PCI treatment initially cost more, however, the cost became similar after three years to those that received FFR guided PCI due to the increased risk of secondary procedures. This suggest that using FFR guided PCU can improve patient outcomes and be just as cost effective as placing a stent without FFR (Fearon et al., 2018).

Mean cumulative medical costs at the initial hospitalization and at 1, 2, and 3 years, along with mean annual follow up costs for patients receiving percutaneous coronary intervention (PCI) + medical therapy (MT) compared with medical therapy alone. Reprinted from Fearon et al. (2018).

Overall, this research supports a more individualized approach to CAD treatment. Instead of automatically treating every visible blockage, physicians can consider blood flow measurements, symptoms, and other patient factors when deciding whether PCI is appropriate. This approach may help patients receive treatments that provide meaningful benefits while avoiding unnecessary invasive procedures.

References

Collet, C., et al. (2026). Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: Long-term results of the FAME 2 trial. Nature Medicine, 32, 318–324. https://doi.org/10.1038/s41591-025-04132-5

De Bruyne, B., et al. (2012). Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. New England Journal of Medicine, 367(11), 991–1001. https://doi.org/10.1038/s41591-025-04132-5

Fearon, W. F., et al. (2018). Clinical outcomes and cost-effectiveness of fractional flow reserve-guided PCI in patients with stable coronary artery disease. Circulation, 137(5), 480–487. https://doi.org/10.1161/CIRCULATIONAHA.117.031907

The Keyhole Heart Clinic. (2021, April 15). Coronary artery disease: treatment, causes & prevention. https://www.thekeyholeheartclinic.com/blog/coronary-artery-disease-causes-treatments-and-prevention-methods/